Science News

Nobel Prize Discoveries Pave Way for Curing Mind and Sight Diseases

BrightFocus Grantee Connects with Laureate’s ‘Disciples’

October 6, 2016
The Mainichi Newspapers Co., Ltd
Yoshinori Ohsumi, PhD, at Tokyo Institute of Technology after his Nobel prize was announced.

A Short History of A Long Journey

Dr. Ohsumi in 2012.
Associated Press
Dr. Ohsumi in 2012.

The journey to a Nobel prize starts with a lab, a hunch, a well-designed experiment, and funding to carry it out.

The payoff can take decades. Only now are Ohsumi’s basic science experiments of a quarter century ago starting to bear fruit as concepts for stopping disease.

As a young investigator, Ohsami had a few false starts. He started out in chemistry, then switched to molecular biology, earning his PhD from the University of Tokyo in 1974. He struggled to find a job and wound up as a postdoc position studying in vitro fertilization in mice.

He again switched course and began researching duplication of DNA in yeast. That led him back to the University of Tokyo in a junior faculty position. It was there, at age 43, Ohsumi undertook his Nobel prize-winning experiments.

At a news conference this week in Tokyo, the 71-year-old Ohsumi said that he deliberately chose to work on something that not many others were interested in. From a Wall Street Journal report:

“I started my research in what everyone thought was a place for garbage collection, and I began in an era when no one had much interest in the degradation of proteins…

“I don’t like competition very much, and I think the essence of science—what really makes it so much fun—is to do what others aren’t doing, rather than doing what everyone else in the pack is flocking to,” Ohsumi said.


As it turned out, his experiments illustrated a basic concept of life and renewal: that cells shed and recycle substances they no longer need. “Life is possible only with this extremely important recycling system,” Ohsumi said. “We create proteins and destroy them, and again create and destroy, and that’s what makes life exist.”

Now we also know that autophagy declines as cells age. In laboratory experiments, researchers are looking for ways to prevent that decline. Gene therapy and other ways of regulating autophagy are being explored for diverse conditions including cancer and age-related neurodegenerative diseases, like Alzheimer’s disease, Parkinson’s disease and macular degeneration.

This year’s Nobel Prize in Medicine went to a 71-year-old Japanese cell biologist for his discoveries involving autophagy. That work—a quantum leap forward in our understanding of how cells work in the human body—laid the foundation for potential cures for diseases of mind and sight, including research funded by BrightFocus. [See list at end.]

This year’s winner, Yoshinori Ohsumi, PhD, of the Tokyo Institute of Technology, was honored for his work elucidating autophagy, a cellular form of waste disposal and recycling that helps defend and renew many cells in the body, including the precious nerve cells of the eye and brain.

“Autophagy” originates from the Greek words auto-, meaning “self,” and phagein, meaning “to eat.” This concept of cellular "self eating” was seen as early as the 1960s, when researchers noticed that a cell could destroy its own contents by first enclosing them in membranes, then transporting them to a recycling compartment (called a “lysosome”) for degradation.

However, autophagy’s significance wasn’t well understood until the early 1990s, when Ohsumi carried out a series of experiments with yeast cells. He was able to show how autophagy recycles or disposes contents of cells as part of keeping them healthy, and identified some of the genes involved.

Ohsumi and colleagues also established that similar sophisticated machinery is used by human cells. Autophagy is one of the ways our cells have of resisting infection, adapting to starvation, and removing unwanted and/or diseased parts. When autophagy stops working, the result can be disease or cell death.

Role in Macular Degeneration and Alzheimer’s

“It’s amazing work, and something that may affect many diseases,” BrightFocus grantee Debasish Sinha, PhD, of Johns Hopkins Wilmer Eye Institute, said of Ohsumi’s foundational work to explain autophagy.

Sinha is using a new 2016-18 grant from BrightFocus’ Macular Degeneration Research (MDR) program, as well as a recently completed 2014-16 grant, to study the role of autophagy in age-related macular degeneration (AMD).

BrightFocus MDR grantee Debasish Sinha, PhD, Johns Hopkins
BrightFocus MDR grantee Debasish Sinha, PhD, Johns Hopkins
The retinal pigmented epithelium (RPE) of the eye, which nourishes the light-sensing photoreceptors of the retina, depends on autophagy to function properly. Like most nerve cells in the body, RPE cells are non-dividing, meaning they can’t replace themselves when injured or depleted, unlike skin and cells of other tissues. Instead, the RPE relies on autophagy to stay in mint condition.

Among other things, autophagy helps RPE cells dispose of and recycle “used” parts of the retina, including photoreceptor end segments, which burn out and need to be discarded about every 10 days. “Here you have a highly metabolic cell that doesn’t divide. Instead, it degrades photoreceptor end segments by deleting various amino acids and recycling them through the body,” Sinha said.

Autophagy also helps clear the retina of lipids and other debris that could provoke inflammation. Current thinking holds that macular degeneration actually begins in the RPE, when drusen, inflammation, and other threats begin to erode the health of RPE tissue.

Sinha and other BrightFocus grantees are investigating how disruptions in autophagy, caused by age and environmental factors, may contribute to the disease process. They are also tracing the genetic signaling involved. [For a review of some of these investigations, read our recent Science News report.]

Yet autophagy’s importance doesn’t end with the eye. “This is something that may affect many diseases,” Sinha emphasized. For example, Alzheimer’s researchers are asking, “where do [tau] tangles come from?’” and many are speculating that “it’s because the cell does not recycle properly,” Sinha said.

Thus, for AMD, cancer, Alzheimer’s, and other neurodegenerative diseases of mind and sight, Ohsumi’s discoveries loom large. “Many experts acknowledge that this process [autophagy] will play a big role in solving these diseases,” Sinha said.

Less Than a Week Ago, Hosting the Laureate’s Lab Team

Since the Nobel announcement earlier this week, cell biologists around the world have been endorsing Ohsumi’s selection for the prize. Many, like Sinha, have long marveled at the power to cure disease that was unleashed by Ohsumi’s innovative experiments.

In Sinha’s case, there’s also a personal connection. He’s been inspired by Ohsumi’s work, and spoken directly with the Nobel laureate at past international meetings, most recently at an autophagy meeting in China last year.

Also, less than a week ago, Sinha arranged for two close disciples of Ohsumi’s to speak at a session he chaired at the International Society of Eye Research (ISER) meeting in Tokyo.

Noboru Mizushima, PhD, and Tamotsu Yoshimori, PhD, got their start as researchers working in Ohsumi’s lab in the 1990s. Both of them appear as coauthors on a short list of four publications circulated by the Nobel committee in connection with Ohsumi’s work.

Tamotsu Yoshimori PhD, of Osaka University, left, and Noboru Mizushima, PhD, of Tokyo University, helped carry out the prize-winning experiments.
Tamotsu Yoshimori PhD, of Osaka University, left, and Noboru Mizushima, PhD, of Tokyo University, helped carry out the prize-winning experiments.

This week, in a Wall Street Journal article, Ohsumi named both colleagues as significant contributors to his work, and said he’d considered sharing the award with them:

…shortly before he heard the news, he had been speculating in his own mind that if he were to win the Nobel Prize, he might share it with Noboru Mizushima, a Tokyo University professor, and Tamotsu Yoshimori, an Osaka University professor, both of whom have done significant work in autophagy.

“As chairman, I arranged for both [Mizushima and Yoshimori] to speak at my ISER session entitled ‘Autophagy in Eye Health and Disorders,’ ” Sinha said. “And they kindly accepted the invitation.”

“I always believed Ohsumi to be a good mentor. It’s incredible to think that these two guys helped carry out his Nobel prize work when they were in his lab,” Sinha said. Along with Ohsumi, both researchers now are leaders in the field.

“Sometimes [in this field], it’s amazing how close the connections can be!”


BrightFocus-funded Research Into Autophagy

Across all three of its grant programs, BrightFocus is advancing research into autophagy as a way to fight disease. Here are some current projects.

Macular Degeneration Research (MDR)

Cellular Self-Eating: An Important Mechanism in AMD
Nady Golestaneh, PhD
Georgetown University (Washington, DC)

Novel Therapeutic Targets for the Treatment of Early AMD
Debasish Sinha, PhD
Wilmer Eye Institute, Johns Hopkins University School of Medicine (Baltimore, MD)

Insight Into the Formation of Harmful Deposits In the Retina
Aparna Lakkaraju, PhD
University of Wisconsin System (Madison, WI)

Alzheimer’s Disease Research

Stimulating Nerve Cells to Dispose of Unwanted Tau Protein
Gail Johnson, PhD
University of Rochester Medical Center (Rochester, NY)

Understanding Brain Inflammation in Alzheimer's Disease
Zixu Mao, PhD
Emory University (Atlanta, GA)

Restoring a Novel Multifunctional Protein in Neurons to Enhance Cognitive Function in Alzheimer’s Disease
Richard Morrison, PhD
University of Washington School of Medicine (Seattle, WA)

National Glaucoma Research

Use of Patient-Derived Cells to Test Compounds that Will Reverse Exfoliation Glaucoma
Audrey Bernstein, PhD
Icahn School of Medicine at Mount Sinai (New York, NY)

Cell Self-eating as a Protective Mechanism in Glaucoma
Paloma B Liton, PhD
Duke University Eye Center (Durham, NC, United States)

 

The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.

Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Keep me imformed about: *
Please select at least one.
You must select at least one disease category.
Please enter your first name.
Please enter your last name.